※ 본 기사문(영문ver.)은 (주)도프의 이슈를 다룬 기사를 자체적으로 영문번역하였음을 밝힙니다.

DOF Inc. expands the human tissue transplant material market with the world's first supercritical technology

 

기사 원문 :  화성산업진흥원-화성시 기업지원 플랫폼 (hscity.go.kr)

 

 

DOF Inc. (CEO Shin Yong-woo), a tissue-based regenerative medicine company, is the world's first bio venture company that succeeded in commercializing human tissue transplant materials by securing the stability and competitiveness of engraftment using supercritical technology, shortening processing time, and securing cost advantages. DOF's supercritical technology can decellularize human tissues such as skin and nerves without surfactants, and is harmless and safe to the human body by using carbon dioxide (CO2), an eco-friendly process. In addition, by using the supercritical process, the tissue processing time for decellularization, which previously took 3 to 5 days, can be shortened to less than 2 days (skin) and 1 day (nerves), resulting in less tissue destruction, securing cost competitiveness compared to competitors, and tissue storage. This has an advantage.

 

 

   DOF Inc.'s main product is SC DERM, an acellular allogeneic skin, which is mainly used for breast reconstruction after breast cancer surgery, rotator cuff surgery, and skin reconstruction for patients with bedsores and burns. In addition, one of the main products, SC CONNECT, is the first nerve graft material supplied to the domestic market other than Axogen in the United States and is used for patients who have lost nerves due to accidents or breast cancer. In particular, compared to Axogen, DOF's product has an advantage in supply price competition with a supply price of about 42%, and it is possible to enlarge the allogeneic nerve in a specific area when transplanting an existing autologous nerve.

 

 

   CEO Shin Yong-woo said, “We began supplying products to the market in earnest in the second half of last year. “Currently, we are supplying transplant materials to about 10 major university hospitals in Korea, and the number of cases is expected to exceed 2,000 by the end of this year.” “It was high,” he said. “In the future, DOF Inc. will grow into a global medical healthcare company that can contribute to the world and humanity and will contribute to a better life for humanity,” he said.

   Meanwhile, DOF Inc. attracted 1.5 billion won in investment from the Hwaseong City Startup Investment Fund invested by the Hwaseong Industry Promotion Agency last May.